Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350–1355 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507–1517 (2014).

Article  PubMed  PubMed Central  Google Scholar 

Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531–2544 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

McGrail, D. J. et al. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann. Oncol. 32, 661–672 (2021).

Article  CAS  PubMed  Google Scholar 

Bruni, D., Angell, H. K. & Galon, J. The immune contexture and immunoscore in cancer prognosis and therapeutic efficacy. Nat. Rev. Cancer 20, 662–680 (2020).

Article  CAS  PubMed  Google Scholar 

Andrews, M. C. et al. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nat. Med. 27, 1432–1441 (2021).

Article  CAS  PubMed  Google Scholar 

Routy, B. et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359, 91–97 (2018).

Article  CAS  PubMed  Google Scholar 

Matson, V. et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 359, 104–108 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gopalakrishnan, V. et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359, 97–103 (2018). Together with Routy et al. (2018) and Matson et al. (2018), this early study reports a link between the composition of the gut microbiota and clinical response to anti-PD1.

Article  CAS  PubMed  Google Scholar 

Vetizou, M. et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350, 1079–1084 (2015). This landmark publication reports a link between the composition of the gut microbiota and clinical response to ICB (anti-CTLA4).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stein-Thoeringer, C. K. et al. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy. Nat. Med. 29, 906–916 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Smith, M. et al. Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. Nat. Med. 28, 713–723 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hu, Y. et al. CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies. Nat. Commun. 13, 5313 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Blumenberg, V. et al. Antibiotic therapy and low gut microbiome diversity is associated with decreased response and high toxicity in BCP-ALL and DLBCL patients after treatment with CD19. CAR T-cells. Blood 136, 33–34 (2020).

Article  Google Scholar 

Tintelnot, J. et al. Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer. Nature 615, 168–174 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Daillere, R. et al. Enterococcus hirae and Barnesiella intestinihominis facilitate cyclophosphamide-induced therapeutic immunomodulatory effects. Immunity 45, 931–943 (2016).

Article  CAS  PubMed  Google Scholar 

Iida, N. et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 342, 967–970 (2013).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Simpson, R. C. et al. Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome. Nat. Med. 28, 2344–2352 (2022).

Article  CAS  PubMed  Google Scholar 

Blake, S. J. et al. The immunotoxicity, but not anti-tumor efficacy, of anti-CD40 and anti-CD137 immunotherapies is dependent on the gut microbiota. Cell Rep. Med. 2, 100464 (2021). This early study reports that the immunotoxicity, but not antitumour efficacy, of IAAs depends on the gut microbiota in mice.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Peled, J. U. et al. Microbiota as predictor of mortality in allogeneic hematopoietic-cell transplantation. N. Engl. J. Med. 382, 822–834 (2020). This large clinical study identifies that microbiota diversity can predict rates of infection, GVHD and survival following HCT.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dubin, K. et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat. Commun. 7, 10391 (2016).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chua, L. L. et al. Reduced microbial diversity in adult survivors of childhood acute lymphoblastic leukemia and microbial associations with increased immune activation. Microbiome 5, 35 (2017).

Article  PubMed  PubMed Central  Google Scholar 

Oeffinger, K. C. et al. Chronic health conditions in adult survivors of childhood cancer. N. Engl. J. Med. 355, 1572–1582 (2006).

Article  CAS  PubMed  Google Scholar 

Baruch, E. N. et al. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science 371, 602–609 (2021).

Article  CAS  PubMed  Google Scholar 

Davar, D. et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science 371, 595–602 (2021). Together with Baruch et al. (2021), this pioneering phase I clinical study shows that FMT from anti-PD1 responders can confer responsiveness to anti-PD1 in patients with melanoma who were previously unresponsive.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhao, Y. et al. Safety and efficacy of fecal microbiota transplantation for grade IV steroid refractory GI-GvHD patients: interim results from FMT2017002 trial. Front. Immunol. 12, 678476 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Malard, F. et al. Pooled allogenic fecal microbiotherapy MaaT013 for the treatment of steroid-refractory gastrointestinal acute graft-versus-host disease: results from the phase IIa HERACLES study and expanded access program. Blood 138, 262–262 (2021).

Article  Google Scholar 

Shreiner, A. B., Kao, J. Y. & Young, V. B. The gut microbiome in health and in disease. Curr. Opin. Gastroenterol. 31, 69–75 (2015).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vangay, P., Ward, T., Gerber, J. S. & Knights, D. Antibiotics, pediatric dysbiosis, and disease. Cell Host Microbe 17, 553–564 (2015).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nejman, D. et al. The human tumor microbiome is composed of tumor type-specific intracellular bacteria. Science 368, 973–980 (2020). This work highlights the presence of tumour-colonizing bacteria in several cancer types, a paradigm shift in the field.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Narunsky-Haziza, L. et al. Pan-cancer analyses reveal cancer-type-specific fungal ecologies and bacteriome interactions. Cell 185, 3789–3806.e17 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Broecker, F. & Moelling, K. The roles of the virome in cancer. Microorganisms 9, 2538 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wolf, Y. & Samuels, Y. Intratumor heterogeneity and antitumor immunity shape one another bidirectionally. Clin. Cancer Res. 28, 2994–3001 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zitvogel, L., Apetoh, L., Ghiringhelli, F. & Kroemer, G. Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol. 8, 59–73 (2008).

Article  CAS  PubMed  Google Scholar 

Geller, L. T. et al. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science 357, 1156–1160 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Viaud, S. et al. The intestin